Randomized Study Of Fludarabine And Cyclophosphamide With Or Without Genasense (Bcl-2 Antisense Oligonucleotide) [oblimersen] In Subjects With Relapsed Or Refractory Chronic Lymphocytic Leukemia

Trial Profile

Randomized Study Of Fludarabine And Cyclophosphamide With Or Without Genasense (Bcl-2 Antisense Oligonucleotide) [oblimersen] In Subjects With Relapsed Or Refractory Chronic Lymphocytic Leukemia

Completed
Phase of Trial: Phase III

Latest Information Update: 10 Jan 2014

At a glance

  • Drugs Oblimersen (Primary) ; Cyclophosphamide; Fludarabine
  • Indications Chronic lymphocytic leukaemia
  • Focus Registrational; Therapeutic Use
  • Sponsors Genta
  • Most Recent Events

    • 08 Sep 2009 Five-year survival results published in Journal of Clinical Oncology.
    • 04 Jun 2009 Long-term follow-up data was presented at the 14th Congress of the European Hematology Association.
    • 06 Jun 2008 Five-year follow-up data were presented at the 44th American Society of Clinical Oncology (ASCO) annual meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top